Related Experiment Video
Updated: Aug 30, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
[Myocardial protective effect of L-carnitine in cardioplegia solution on patients undergoing heart valve replacement
Dao-kang Xiang1, Xing-zhi Yan, Shi-yu Yang
1Department of Cardiac Surgery, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Insights
L-carnitine in cardiac arresting solution significantly reduces myocardial damage and improves heart function in heart valve replacement patients undergoing cardiopulmonary bypass. This protective effect is dose-dependent, with higher concentrations showing better outcomes.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Context:
- Heart valve replacement surgery often involves cardiopulmonary bypass (CPB), which can lead to myocardial injury.
- Protecting the heart muscle during CPB is crucial for patient outcomes.
Purpose:
- To investigate the myocardial protective effect of L-carnitine when added to cardiac arresting solutions during heart valve replacement operations.
Summary:
- A study involving 69 patients undergoing heart valve replacement compared L-carnitine (12 g/L or 6 g/L) in cardiac arresting solution against a control group.
- Results showed significantly lower levels of cardiac biomarkers (cTnI, AST, LDH, CK, CK-MB), reduced need for vasoactive drugs, higher cardiac auto-rebeating rates, and improved cardiac index (CI) and ejection fraction (EF) in L-carnitine groups.
- Electron microscopy revealed less mitochondrial damage in hearts treated with L-carnitine.
Impact:
- L-carnitine demonstrates a significant protective effect on the myocardium during heart valve replacement surgery with CPB.
- The findings suggest L-carnitine is a valuable adjunct for myocardial protection in this patient population.
- Antegrade coronary perfusion of L-carnitine is recommended for clinical application.
Objective:
To investigate the myocardial protective effect of L-carnitine as an ingredient of cardiac arresting solution in the process of heart valve replacement operation.
Methods:
69 cases undergoing heart valve replacement with cardiopulmonary bypass (CPB), 47 males and 22 females, aged 48.17 +/- 14.22 (16 approximately 74 years), were divided into 3 groups: test group I (n = 22, 12 g/L L-carnitine was put in the St. Thomas II cold crystal cardiac arresting liquid), test group II (n = 24, 6 g/L L-carnitine was put in the St. Thomas II cold crystal cardiac arresting liquid), and control group (n = 23, no L-carnitine was put in the St. Thomas II cold crystal cardiac arresting liquid). Before operation, 20 minutes after the beginning of shunt, after the finish of shunt, and 8 hours, one day, 3 days, and 7 days after operation venous blood was drawn to test the serum cardial tropnin I (cTnI), aspartate transaminase, lactate dehydrogenase, creatine kinase (CK) and CK-MB isozyme. Heart color ultrasonography was conducted to test the cardiac index (CI) and left heart ejecting fraction (EF) one day before operation and 7 days after operation. Before shunt and by the end of intracardiac procedure a bit of myocardial tissue was taken to undergo electron microscopy. The amounts of vaso-active drugs, such as dopamine and dobutamine, used postoperatively, and the postoperative cardiac auto-rebeating rate were recorded.
Results:
The Amounts of vaso-active drugs used after operation was 329 +/- 54 mg in the test group I and 339 +/- 47 mg in the test group II, both significantly less than in the control group (669 +/- 56 mg, both P < 0.01) without a significant difference between the 2 test groups. Since the end of CPB to 3 days after operation, the serum levels of cTnI, aspartate transaminase, lactate dehydrogenase, CK and CK-MB isozyme were significantly lower in the 2 test groups than in the control group (P < 0.05 or P < 0.01). The serum level of cTnI in test group I was significantly lower than in the test group II (5.71 +/- 1.14 ng/ml vs 7.87 +/- 1.89 ng/ml 1 day postoperatively (P < 0.05), and 5.01 +/- 0.89 ng/ml vs 7.53 +/- 1.43 ng/ml 3 days postoperatively (P < 0.05). The postoperative cardiac auto-rebeating rate was 87.9% in the test group I and 74.3% in the test group II, both significantly higher than that in the control group (45.7%, P < 0.05 and P < 0.01). Heart color ultrasonogram showed that 7 days postoperatively the CI index was 2.86 +/- 0.55 and 2.74 +/- 0.56 in the 2 test groups, significantly higher than that in the control group (2.11 +/- 0.35, both P < 0.05), and the left heart EF were 64.3 +/- 8.6 and 59.1 +/- 6.7 in the 2 test groups, both significantly higher than that in the control group (51.7 +/- 4.9, both P < 0.05). Electron microscopy showed only slight swelling of mitochondria in the cardial cell and the myocardial fiber was intact by the end of operation in the 2 test groups without significant difference between these 2 groups, however, in the control group swelling of mitochondria with vesicle formation, fissure of part of mitochondrial ridges, and disappearance of glycogen particles were found.
Conclusion:
Antegrade coronary perfusion of L-carnitine has a good protective effect on myocardium and is worth spreading for heart valve replacement patients with cardiopulmonary bypass.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure Drugs: Inotropic Agents
Coronary Artery Disease V: Interprofessional Care

